Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $55.80.

Several analysts recently commented on PTHS shares. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Oppenheimer lifted their target price on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Piper Sandler initiated coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, Roth Mkm dropped their target price on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th.

Pelthos Therapeutics Stock Performance

PTHS stock opened at $27.50 on Monday. The firm has a market capitalization of $95.70 million, a price-to-earnings ratio of -1.33 and a beta of 3.17. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. The firm’s fifty day moving average price is $25.10. Pelthos Therapeutics has a one year low of $11.20 and a one year high of $54.29.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The company had revenue of $10.91 million for the quarter. Research analysts predict that Pelthos Therapeutics will post -11.7 earnings per share for the current fiscal year.

Institutional Trading of Pelthos Therapeutics

Institutional investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd grew its position in shares of Pelthos Therapeutics by 150.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares during the period. Pale Fire Capital SE grew its position in shares of Pelthos Therapeutics by 59.5% in the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after purchasing an additional 4,819 shares during the period. Millennium Management LLC acquired a new position in Pelthos Therapeutics during the fourth quarter worth about $343,000. Geode Capital Management LLC boosted its position in Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after acquiring an additional 3,295 shares during the last quarter. Finally, Knott David M Jr boosted its position in Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after acquiring an additional 1,792 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).